;PMID: 8907200 ;source_file_1409.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..36] = [t:0..36] ;1)sentence:[e:41..195] = [t:41..195] ;2)section:[e:199..255] = [t:199..255] ;3)section:[e:259..298] = [t:259..298] ;4)sentence:[e:302..482] = [t:302..482] ;5)sentence:[e:483..594] = [t:483..594] ;6)sentence:[e:595..755] = [t:595..755] ;7)sentence:[e:756..860] = [t:756..860] ;8)sentence:[e:861..1026] = [t:861..1026] ;9)sentence:[e:1027..1160] = [t:1027..1160] ;10)sentence:[e:1162..1376] = [t:1162..1376] ;11)sentence:[e:1377..1511] = [t:1377..1511] ;12)section:[e:1515..1559] = [t:1515..1559] ;section 0 Span:0..36 ;Cancer Detect Prev 1996;20(1):20-30 (SEC (FRAG (NN:[0..6] Cancer) (NNP:[7..13] Detect) (NNP:[14..18] Prev) (CD:[20..28] 1996;20-LRB-) (CD:[28..29] 1) (-RRB-:[29..30] -RRB-) (CD:[30..33] :20) (::[33..34] -) (CD:[34..36] 30))) ;sentence 1 Span:41..195 ;A possible role for human papillomaviruses and c-myc, c-Ha-ras, and p53 gene ;alterations in malignant cutaneous lesions from renal transplant recipients. ;[88..93]:gene-rna:"c-myc" ;[95..103]:gene-rna:"c-Ha-ras" ;[109..112]:gene-rna:"p53" ;[134..161]:malignancy:"malignant cutaneous lesions" (SENT (NP-HLN (NP (DT:[41..42] A) (JJ:[43..51] possible) (NN:[52..56] role)) (PP (IN:[57..60] for) (NP (NP (JJ:[61..66] human) (NNS:[67..83] papillomaviruses)) (CC:[84..87] and) (NP (NP (NN:[88..93] c-myc) (NML-1 (-NONE-:[93..93] *P*))) (,:[93..94] ,) (NP (NN:[95..103] c-Ha-ras) (NML-1 (-NONE-:[103..103] *P*))) (,:[103..104] ,) (CC:[105..108] and) (NP (NN:[109..112] p53) (NML-1 (NN:[113..117] gene) (NNS:[119..130] alterations)))))) (PP-LOC (IN:[131..133] in) (NP (NP (JJ:[134..143] malignant) (JJ:[144..153] cutaneous) (NNS:[154..161] lesions)) (PP (IN:[162..166] from) (NP (JJ:[167..172] renal) (NN:[173..183] transplant) (NNS:[184..194] recipients))))) (.:[194..195] .))) ;section 2 Span:199..255 ;Pelisson I, Soler C, Chardonnet Y, Euvrard S, Schmitt D. (SEC (FRAG (IN:[199..207] Pelisson) (PRP:[208..209] I) (,:[209..210] ,) (NNP:[211..216] Soler) (NNP:[217..218] C) (,:[218..219] ,) (NNP:[220..230] Chardonnet) (NNP:[231..232] Y) (,:[232..233] ,) (NNP:[234..241] Euvrard) (NNP:[242..244] S,) (NNP:[245..252] Schmitt) (NNP:[253..255] D.))) ;section 3 Span:259..298 ;Edouard Herriot Hospital, Lyon, France. (SEC (FRAG (NNP:[259..266] Edouard) (NNP:[267..274] Herriot) (NNP:[275..283] Hospital) (,:[283..284] ,) (NNP:[285..289] Lyon) (,:[289..290] ,) (NNP:[291..297] France) (.:[297..298] .))) ;sentence 4 Span:302..482 ;Several years after transplantation, renal transplant recipients develop ;numerous cutaneous squamous cell carcinomas (SCC), in which human ;papillomaviruses (HPV) may be detected. ;[385..419]:malignancy:"cutaneous squamous cell carcinomas" ;[421..424]:malignancy:"SCC" (SENT (S (NP-TMP (NP (JJ:[302..309] Several) (NNS:[310..315] years)) (PP (IN:[316..321] after) (NP (NN:[322..337] transplantation)))) (,:[337..338] ,) (NP-SBJ (JJ:[339..344] renal) (NN:[345..355] transplant) (NNS:[356..366] recipients)) (VP (VBP:[367..374] develop) (NP (NP (JJ:[376..384] numerous) (JJ:[385..394] cutaneous) (NML (NML (JJ:[395..403] squamous) (NN:[404..408] cell) (NNS:[409..419] carcinomas)) (NML (-LRB-:[420..421] -LRB-) (NN:[421..424] SCC) (-RRB-:[424..425] -RRB-)))) (,:[425..426] ,) (SBAR (WHPP-2 (IN:[427..429] in) (WHNP (WDT:[430..435] which))) (S (NP-SBJ-1 (NP (JJ:[436..441] human) (NNS:[443..459] papillomaviruses)) (NP (-LRB-:[460..461] -LRB-) (NN:[461..464] HPV) (-RRB-:[464..465] -RRB-))) (VP (MD:[466..469] may) (VP (VB:[470..472] be) (VP (VBN:[473..481] detected) (NP-1 (-NONE-:[481..481] *)) (PP-LOC-2 (-NONE-:[481..481] *T*))))))))) (.:[481..482] .))) ;sentence 5 Span:483..594 ;Alterations in c-myc, c-Ha-ras, and p53 genes were studied in 34 SCC, in ;correlation with the presence of HPV. ;[498..503]:gene-rna:"c-myc" ;[505..513]:gene-rna:"c-Ha-ras" ;[519..522]:gene-rna:"p53" ;[549..552]:malignancy:"SCC" (SENT (S (NP-SBJ-2 (NP (NNS:[483..494] Alterations)) (PP-LOC (IN:[495..497] in) (NP (NP (NN:[498..503] c-myc) (NML-1 (-NONE-:[503..503] *P*))) (,:[503..504] ,) (NP (NN:[505..513] c-Ha-ras) (NML-1 (-NONE-:[513..513] *P*))) (,:[513..514] ,) (CC:[515..518] and) (NP (NN:[519..522] p53) (NML-1 (NNS:[524..529] genes)))))) (VP (VBD:[530..534] were) (VP (VBN:[535..542] studied) (NP-2 (-NONE-:[542..542] *)) (PP (IN:[543..545] in) (NP (CD:[546..548] 34) (NN:[549..552] SCC))) (,:[552..553] ,) (PP (IN:[554..556] in) (NP (NP (NN:[557..568] correlation)) (PP (IN:[569..573] with) (NP (NP (DT:[574..577] the) (NN:[578..586] presence)) (PP (IN:[587..589] of) (NP (NN:[590..593] HPV))))))))) (.:[593..594] .))) ;sentence 6 Span:595..755 ;In situ hybridization (ISH) and polymerase chain reaction (PCR) showed that ;many SCC contained several HPV types infecting different foci of epithelial ;cells. ;[628..638]:gene-protein:"polymerase" ;[677..680]:malignancy:"SCC" (SENT (S (NP-SBJ (NP (NP (FW:[595..597] In) (FW:[598..602] situ) (NN:[604..617] hybridization)) (NP (-LRB-:[618..619] -LRB-) (NN:[619..622] ISH) (-RRB-:[622..623] -RRB-))) (CC:[624..627] and) (NP (NP (NN:[628..638] polymerase) (NN:[639..644] chain) (NN:[645..653] reaction)) (NP (-LRB-:[654..655] -LRB-) (NN:[655..658] PCR) (-RRB-:[658..659] -RRB-)))) (VP (VBD:[660..666] showed) (SBAR (IN:[667..671] that) (S (NP-SBJ (JJ:[672..676] many) (NN:[677..680] SCC)) (VP (VBD:[682..691] contained) (NP (NP (JJ:[692..699] several) (NN:[700..703] HPV) (NNS:[704..709] types)) (VP (VBG:[710..719] infecting) (NP (NP (JJ:[720..729] different) (NNS:[730..734] foci)) (PP (IN:[735..737] of) (NP (JJ:[738..748] epithelial) (NNS:[749..754] cells)))))))))) (.:[754..755] .))) ;sentence 7 Span:756..860 ;Using Southern blot and ISH, c-myc and/or c-Ha-ras gene amplification was ;detected in 7/13 SCC tested. ;[786..791]:gene-rna:"c-myc" ;[799..807]:gene-rna:"c-Ha-ras" ;[849..852]:malignancy:"SCC" (SENT (S (S-MNR (NP-SBJ (-NONE-:[756..756] *)) (VP (VBG:[756..761] Using) (NP (NP (JJ:[763..771] Southern) (NN:[772..776] blot)) (CC:[777..780] and) (NP (NN:[781..784] ISH))))) (,:[784..785] ,) (NP-SBJ-2 (NP (NN:[786..791] c-myc) (NML-1 (-NONE-:[791..791] *P*))) (CC:[792..798] and/or) (NP (NN:[799..807] c-Ha-ras) (NML-1 (NN:[808..812] gene) (NN:[813..826] amplification)))) (VP (VBD:[827..830] was) (VP (VBN:[831..839] detected) (NP-2 (-NONE-:[839..839] *)) (PP-LOC (IN:[840..842] in) (NP (NP (CD:[844..845] 7)) (PP (SYM:[845..846] /) (NP (NP (CD:[846..848] 13) (NN:[849..852] SCC)) (VP (VBN:[853..859] tested) (NP (-NONE-:[859..859] *))))))))) (.:[859..860] .))) ;sentence 8 Span:861..1026 ;With PCR and oligoprobe hybridization, a GGC -> GAC mutation was found at ;codon 12 of c-Ha-ras gene in 1/21 SCC tested, while no mutation was detected ;at codon 61. ;[902..905]:variation-state-original:"GGC" ;[909..912]:variation-state-altered:"GAC" ;[913..921]:variation-event:"mutation" ;[936..944]:variation-location:"codon 12" ;[948..956]:gene-rna:"c-Ha-ras" ;[970..973]:malignancy:"SCC" ;[1017..1025]:variation-location:"codon 61" (SENT (S (PP-MNR (IN:[861..865] With) (NP (NP (NN:[866..869] PCR)) (CC:[870..873] and) (NP (NN:[874..884] oligoprobe) (NN:[885..898] hybridization)))) (,:[898..899] ,) (NP-SBJ-2 (DT:[900..901] a) (NML (NML (NN:[902..905] GGC)) (PP (SYM:[906..908] ->) (NP (NN:[909..912] GAC)))) (NN:[913..921] mutation)) (VP (VBD:[923..926] was) (VP (VBN:[927..932] found) (NP-2 (-NONE-:[932..932] *)) (PP-LOC (IN:[933..935] at) (NP (NP (NN:[936..941] codon) (CD:[942..944] 12)) (PP (IN:[945..947] of) (NP (NN:[948..956] c-Ha-ras) (NN:[957..961] gene))))) (PP-LOC (IN:[962..964] in) (NP (NP (CD:[965..966] 1)) (PP (SYM:[966..967] /) (NP (NP (CD:[967..969] 21) (NN:[970..973] SCC)) (VP (VBN:[974..980] tested) (NP (-NONE-:[980..980] *))))))) (,:[980..981] ,) (SBAR-ADV (IN:[982..987] while) (S (NP-SBJ-1 (DT:[988..990] no) (NN:[991..999] mutation)) (VP (VBD:[1000..1003] was) (VP (VBN:[1005..1013] detected) (NP-1 (-NONE-:[1013..1013] *)) (PP-LOC (IN:[1014..1016] at) (NP (NN:[1017..1022] codon) (CD:[1023..1025] 61))))))))) (.:[1025..1026] .))) ;sentence 9 Span:1027..1160 ;Using immunohistochemistry, p53 protein expression was detected either along ;the basal cell layer or spotted in foci of basal cells. ;[1055..1058]:gene-protein:"p53" (SENT (S (S-MNR (NP-SBJ (-NONE-:[1027..1027] *)) (VP (VBG:[1027..1032] Using) (NP (NN:[1033..1053] immunohistochemistry)))) (,:[1053..1054] ,) (NP-SBJ-1 (NN:[1055..1058] p53) (NN:[1059..1066] protein) (NN:[1067..1077] expression)) (VP (VBD:[1078..1081] was) (VP (VBN:[1083..1091] detected) (NP-1 (-NONE-:[1091..1091] *)) (UCP (CC:[1092..1098] either) (PP (IN:[1099..1104] along) (NP (DT:[1105..1108] the) (JJ:[1109..1114] basal) (NN:[1115..1119] cell) (NN:[1120..1125] layer))) (CC:[1126..1128] or) (VP (VBN:[1129..1136] spotted) (NP-1 (-NONE-:[1136..1136] *)) (PP-LOC (IN:[1137..1139] in) (NP (NP (NNS:[1140..1144] foci)) (PP (IN:[1145..1147] of) (NP (JJ:[1148..1153] basal) (NNS:[1154..1159] cells))))))))) (.:[1159..1160] .))) ;sentence 10 Span:1162..1376 ;Our results show an abnormal distribution of HPV types in SCC from renal ;transplant recipients, and alterations of c-myc, c-Ha-ras, and p53 genes ;without any direct link with the presence of any studied HPV type. ;[1220..1223]:malignancy:"SCC" ;[1278..1283]:gene-rna:"c-myc" ;[1285..1293]:gene-rna:"c-Ha-ras" ;[1299..1302]:gene-rna:"p53" (SENT (S (NP-SBJ (PRP$:[1162..1165] Our) (NNS:[1166..1173] results)) (VP (VBP:[1174..1178] show) (NP (NP (NP (DT:[1179..1181] an) (JJ:[1182..1190] abnormal) (NN:[1191..1203] distribution)) (PP (IN:[1204..1206] of) (NP (NN:[1207..1210] HPV) (NNS:[1211..1216] types))) (PP-LOC (IN:[1217..1219] in) (NP (NP (NN:[1220..1223] SCC)) (PP (IN:[1224..1228] from) (NP (JJ:[1229..1234] renal) (NN:[1236..1246] transplant) (NNS:[1247..1257] recipients)))))) (,:[1257..1258] ,) (CC:[1259..1262] and) (NP (NP (NP (NNS:[1263..1274] alterations)) (PP (IN:[1275..1277] of) (NP (NP (NN:[1278..1283] c-myc) (NML-1 (-NONE-:[1283..1283] *P*))) (,:[1283..1284] ,) (NP (NN:[1285..1293] c-Ha-ras) (NML-1 (-NONE-:[1293..1293] *P*))) (,:[1293..1294] ,) (CC:[1295..1298] and) (NP (NN:[1299..1302] p53) (NML-1 (NNS:[1303..1308] genes)))))) (PP (IN:[1309..1316] without) (NP (NP (DT:[1318..1321] any) (JJ:[1322..1328] direct) (NN:[1329..1333] link)) (PP (IN:[1334..1338] with) (NP (NP (DT:[1339..1342] the) (NN:[1343..1351] presence)) (PP (IN:[1352..1354] of) (NP (DT:[1355..1358] any) (VBN:[1359..1366] studied) (NN:[1367..1370] HPV) (NN:[1371..1375] type)))))))))) (.:[1375..1376] .))) ;sentence 11 Span:1377..1511 ;Thus, viral infection and oncogene activation may represent factors involved ;in the etiology of skin SCC from transplant recipients. ;[1474..1483]:malignancy:"skin SCC" (SENT (S (ADVP (RB:[1377..1381] Thus)) (,:[1381..1382] ,) (NP-SBJ (NP (JJ:[1383..1388] viral) (NN:[1389..1398] infection)) (CC:[1400..1403] and) (NP (NN:[1404..1412] oncogene) (NN:[1413..1423] activation))) (VP (MD:[1424..1427] may) (VP (VB:[1428..1437] represent) (NP (NP (NNS:[1438..1445] factors)) (VP (VBN:[1446..1454] involved) (NP (-NONE-:[1454..1454] *)) (PP-CLR (IN:[1455..1457] in) (NP (NP (DT:[1458..1461] the) (NN:[1462..1470] etiology)) (PP (IN:[1471..1473] of) (NP (NP (NN:[1474..1478] skin) (NN:[1480..1483] SCC)) (PP (IN:[1484..1488] from) (NP (NN:[1489..1499] transplant) (NNS:[1500..1510] recipients))))))))))) (.:[1510..1511] .))) ;section 12 Span:1515..1559 ;PMID: 8907200 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1515..1519] PMID) (::[1519..1520] :) (CD:[1521..1528] 8907200) (IN:[1529..1530] -LSB-) (NNP:[1530..1536] PubMed) (HYPH:[1537..1538] -) (JJ:[1539..1546] indexed) (IN:[1547..1550] for) (NNP:[1551..1559] MEDLINE-RSB-)))